The Protective Role of Fucosylated Chondroitin Sulfate, a Distinct Glycosaminoglycan, in a Murine Model of Streptozotocin-Induced Diabetic Nephropathy: e106929

Background Heparanase-1 activation, albuminuria, and a decrease in glomerular heparan sulfate (HS) have been described in diabetic nephropathy (DN). Glycosaminoglycan (GAG)-based drugs have been shown to have renoprotective effects in this setting, although recent trials have questioned their clinic...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:PloS one 2014-09, Vol.9 (9)
Hauptverfasser: Gomes, Conrado LR, Leao, Cristina L, Venturotti, Carolina, Barreira, Andre L, Guimaraes, Gabriela, Fonseca, Roberto JC, tunato, Rodrigo S, Mourao, Paulo AS, Delgado, Alvimar G, Takiya, Christina M
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 9
container_start_page
container_title PloS one
container_volume 9
creator Gomes, Conrado LR
Leao, Cristina L
Venturotti, Carolina
Barreira, Andre L
Guimaraes, Gabriela
Fonseca, Roberto JC
tunato, Rodrigo S
Mourao, Paulo AS
Delgado, Alvimar G
Takiya, Christina M
description Background Heparanase-1 activation, albuminuria, and a decrease in glomerular heparan sulfate (HS) have been described in diabetic nephropathy (DN). Glycosaminoglycan (GAG)-based drugs have been shown to have renoprotective effects in this setting, although recent trials have questioned their clinical effectiveness. Here, we describe the effects of fucosylated chondroitin sulfate (FCS), a novel GAG extracted from a marine echinoderm, in experimentally induced DN compared to a widely used GAG, enoxaparin (ENX). Methods Diabetes mellitus (DM) was induced by streptozotocin in male Wistar rats divided into three groups: DM (without treatment), FCS (8 mg/kg), and ENX (4 mg/kg), administered subcutaneously. After 12 weeks, we measured blood glucose, blood pressure, albuminuria, and renal function. The kidneys were evaluated for mesangial expansion and collagen content. Immunohistochemical quantifications of macrophages, TGF- beta , nestin and immunofluorescence analysis of heparanase-1 and glomerular basement membrane (GBM) HS content was also performed. Gene expression of proteoglycan core proteins and enzymes involved in GAG assembly/degradation were analyzed by TaqMan real-time PCR. Results Treatment with GAGs prevented albuminuria and did not affect the glucose level or other functional aspects. The DM group exhibited increased mesangial matrix deposition and tubulointerstitial expansion, and prevention was observed in both GAG groups. TGF- beta expression and macrophage infiltration were prevented by the GAG treatments, and podocyte damage was halted. The diabetic milieu resulted in the down-regulation of agrin, perlecan and collagen XVIII mRNAs, along with the expression of enzymes involved in GAG biosynthesis. Treatment with FCS and ENX positively modulated such changes. Heparanase-1 expression was significantly reduced after GAG treatment without affecting the GBM HS content, which was uniformly reduced in all of the diabetic animals. Conclusions Our results demonstrate that the administration of FCS prevented several pathological features of ND in rats. This finding should stimulate further research on GAG treatment for this complication of diabetes.
doi_str_mv 10.1371/journal.pone.0106929
format Article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_miscellaneous_1611611977</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1611611977</sourcerecordid><originalsourceid>FETCH-proquest_miscellaneous_16116119773</originalsourceid><addsrcrecordid>eNqVjs9Kw0AYxBdBsFrfwMN39NDE3QQT47W16qFSbO9l3XwxW7b7xf0jxJfxVd2iLyAMzDD8GIaxK8FzUdbiZk_RWWnygSzmXPCqKZoTNhFNWWRVwcszdu79nvPb8q6qJux72yOsHQVUQX8ivJJBoA6WUZEfjQzYwrwn2zrSQVvYRNOlcgYSFtqnRgV4NGOC5UFbek9R2hkkUsIqOm0RVtSiOW5ugsMh0BcFUtpmz7aNKs0vtHzDoBW84NA7GmTox3vA3-tTdtpJ4_Hyzy_Y9fJhO3_KBkcfEX3YHbRXaIy0SNHvRCWOauq6_Af6A7TWZqI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1611611977</pqid></control><display><type>article</type><title>The Protective Role of Fucosylated Chondroitin Sulfate, a Distinct Glycosaminoglycan, in a Murine Model of Streptozotocin-Induced Diabetic Nephropathy: e106929</title><source>DOAJ Directory of Open Access Journals</source><source>Public Library of Science (PLoS)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Gomes, Conrado LR ; Leao, Cristina L ; Venturotti, Carolina ; Barreira, Andre L ; Guimaraes, Gabriela ; Fonseca, Roberto JC ; tunato, Rodrigo S ; Mourao, Paulo AS ; Delgado, Alvimar G ; Takiya, Christina M</creator><creatorcontrib>Gomes, Conrado LR ; Leao, Cristina L ; Venturotti, Carolina ; Barreira, Andre L ; Guimaraes, Gabriela ; Fonseca, Roberto JC ; tunato, Rodrigo S ; Mourao, Paulo AS ; Delgado, Alvimar G ; Takiya, Christina M</creatorcontrib><description>Background Heparanase-1 activation, albuminuria, and a decrease in glomerular heparan sulfate (HS) have been described in diabetic nephropathy (DN). Glycosaminoglycan (GAG)-based drugs have been shown to have renoprotective effects in this setting, although recent trials have questioned their clinical effectiveness. Here, we describe the effects of fucosylated chondroitin sulfate (FCS), a novel GAG extracted from a marine echinoderm, in experimentally induced DN compared to a widely used GAG, enoxaparin (ENX). Methods Diabetes mellitus (DM) was induced by streptozotocin in male Wistar rats divided into three groups: DM (without treatment), FCS (8 mg/kg), and ENX (4 mg/kg), administered subcutaneously. After 12 weeks, we measured blood glucose, blood pressure, albuminuria, and renal function. The kidneys were evaluated for mesangial expansion and collagen content. Immunohistochemical quantifications of macrophages, TGF- beta , nestin and immunofluorescence analysis of heparanase-1 and glomerular basement membrane (GBM) HS content was also performed. Gene expression of proteoglycan core proteins and enzymes involved in GAG assembly/degradation were analyzed by TaqMan real-time PCR. Results Treatment with GAGs prevented albuminuria and did not affect the glucose level or other functional aspects. The DM group exhibited increased mesangial matrix deposition and tubulointerstitial expansion, and prevention was observed in both GAG groups. TGF- beta expression and macrophage infiltration were prevented by the GAG treatments, and podocyte damage was halted. The diabetic milieu resulted in the down-regulation of agrin, perlecan and collagen XVIII mRNAs, along with the expression of enzymes involved in GAG biosynthesis. Treatment with FCS and ENX positively modulated such changes. Heparanase-1 expression was significantly reduced after GAG treatment without affecting the GBM HS content, which was uniformly reduced in all of the diabetic animals. Conclusions Our results demonstrate that the administration of FCS prevented several pathological features of ND in rats. This finding should stimulate further research on GAG treatment for this complication of diabetes.</description><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0106929</identifier><language>eng</language><ispartof>PloS one, 2014-09, Vol.9 (9)</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,864,27923,27924</link.rule.ids></links><search><creatorcontrib>Gomes, Conrado LR</creatorcontrib><creatorcontrib>Leao, Cristina L</creatorcontrib><creatorcontrib>Venturotti, Carolina</creatorcontrib><creatorcontrib>Barreira, Andre L</creatorcontrib><creatorcontrib>Guimaraes, Gabriela</creatorcontrib><creatorcontrib>Fonseca, Roberto JC</creatorcontrib><creatorcontrib>tunato, Rodrigo S</creatorcontrib><creatorcontrib>Mourao, Paulo AS</creatorcontrib><creatorcontrib>Delgado, Alvimar G</creatorcontrib><creatorcontrib>Takiya, Christina M</creatorcontrib><title>The Protective Role of Fucosylated Chondroitin Sulfate, a Distinct Glycosaminoglycan, in a Murine Model of Streptozotocin-Induced Diabetic Nephropathy: e106929</title><title>PloS one</title><description>Background Heparanase-1 activation, albuminuria, and a decrease in glomerular heparan sulfate (HS) have been described in diabetic nephropathy (DN). Glycosaminoglycan (GAG)-based drugs have been shown to have renoprotective effects in this setting, although recent trials have questioned their clinical effectiveness. Here, we describe the effects of fucosylated chondroitin sulfate (FCS), a novel GAG extracted from a marine echinoderm, in experimentally induced DN compared to a widely used GAG, enoxaparin (ENX). Methods Diabetes mellitus (DM) was induced by streptozotocin in male Wistar rats divided into three groups: DM (without treatment), FCS (8 mg/kg), and ENX (4 mg/kg), administered subcutaneously. After 12 weeks, we measured blood glucose, blood pressure, albuminuria, and renal function. The kidneys were evaluated for mesangial expansion and collagen content. Immunohistochemical quantifications of macrophages, TGF- beta , nestin and immunofluorescence analysis of heparanase-1 and glomerular basement membrane (GBM) HS content was also performed. Gene expression of proteoglycan core proteins and enzymes involved in GAG assembly/degradation were analyzed by TaqMan real-time PCR. Results Treatment with GAGs prevented albuminuria and did not affect the glucose level or other functional aspects. The DM group exhibited increased mesangial matrix deposition and tubulointerstitial expansion, and prevention was observed in both GAG groups. TGF- beta expression and macrophage infiltration were prevented by the GAG treatments, and podocyte damage was halted. The diabetic milieu resulted in the down-regulation of agrin, perlecan and collagen XVIII mRNAs, along with the expression of enzymes involved in GAG biosynthesis. Treatment with FCS and ENX positively modulated such changes. Heparanase-1 expression was significantly reduced after GAG treatment without affecting the GBM HS content, which was uniformly reduced in all of the diabetic animals. Conclusions Our results demonstrate that the administration of FCS prevented several pathological features of ND in rats. This finding should stimulate further research on GAG treatment for this complication of diabetes.</description><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><recordid>eNqVjs9Kw0AYxBdBsFrfwMN39NDE3QQT47W16qFSbO9l3XwxW7b7xf0jxJfxVd2iLyAMzDD8GIaxK8FzUdbiZk_RWWnygSzmXPCqKZoTNhFNWWRVwcszdu79nvPb8q6qJux72yOsHQVUQX8ivJJBoA6WUZEfjQzYwrwn2zrSQVvYRNOlcgYSFtqnRgV4NGOC5UFbek9R2hkkUsIqOm0RVtSiOW5ugsMh0BcFUtpmz7aNKs0vtHzDoBW84NA7GmTox3vA3-tTdtpJ4_Hyzy_Y9fJhO3_KBkcfEX3YHbRXaIy0SNHvRCWOauq6_Af6A7TWZqI</recordid><startdate>20140901</startdate><enddate>20140901</enddate><creator>Gomes, Conrado LR</creator><creator>Leao, Cristina L</creator><creator>Venturotti, Carolina</creator><creator>Barreira, Andre L</creator><creator>Guimaraes, Gabriela</creator><creator>Fonseca, Roberto JC</creator><creator>tunato, Rodrigo S</creator><creator>Mourao, Paulo AS</creator><creator>Delgado, Alvimar G</creator><creator>Takiya, Christina M</creator><scope>7TN</scope><scope>F1W</scope><scope>H95</scope><scope>L.G</scope></search><sort><creationdate>20140901</creationdate><title>The Protective Role of Fucosylated Chondroitin Sulfate, a Distinct Glycosaminoglycan, in a Murine Model of Streptozotocin-Induced Diabetic Nephropathy: e106929</title><author>Gomes, Conrado LR ; Leao, Cristina L ; Venturotti, Carolina ; Barreira, Andre L ; Guimaraes, Gabriela ; Fonseca, Roberto JC ; tunato, Rodrigo S ; Mourao, Paulo AS ; Delgado, Alvimar G ; Takiya, Christina M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_miscellaneous_16116119773</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gomes, Conrado LR</creatorcontrib><creatorcontrib>Leao, Cristina L</creatorcontrib><creatorcontrib>Venturotti, Carolina</creatorcontrib><creatorcontrib>Barreira, Andre L</creatorcontrib><creatorcontrib>Guimaraes, Gabriela</creatorcontrib><creatorcontrib>Fonseca, Roberto JC</creatorcontrib><creatorcontrib>tunato, Rodrigo S</creatorcontrib><creatorcontrib>Mourao, Paulo AS</creatorcontrib><creatorcontrib>Delgado, Alvimar G</creatorcontrib><creatorcontrib>Takiya, Christina M</creatorcontrib><collection>Oceanic Abstracts</collection><collection>ASFA: Aquatic Sciences and Fisheries Abstracts</collection><collection>Aquatic Science &amp; Fisheries Abstracts (ASFA) 1: Biological Sciences &amp; Living Resources</collection><collection>Aquatic Science &amp; Fisheries Abstracts (ASFA) Professional</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gomes, Conrado LR</au><au>Leao, Cristina L</au><au>Venturotti, Carolina</au><au>Barreira, Andre L</au><au>Guimaraes, Gabriela</au><au>Fonseca, Roberto JC</au><au>tunato, Rodrigo S</au><au>Mourao, Paulo AS</au><au>Delgado, Alvimar G</au><au>Takiya, Christina M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Protective Role of Fucosylated Chondroitin Sulfate, a Distinct Glycosaminoglycan, in a Murine Model of Streptozotocin-Induced Diabetic Nephropathy: e106929</atitle><jtitle>PloS one</jtitle><date>2014-09-01</date><risdate>2014</risdate><volume>9</volume><issue>9</issue><eissn>1932-6203</eissn><abstract>Background Heparanase-1 activation, albuminuria, and a decrease in glomerular heparan sulfate (HS) have been described in diabetic nephropathy (DN). Glycosaminoglycan (GAG)-based drugs have been shown to have renoprotective effects in this setting, although recent trials have questioned their clinical effectiveness. Here, we describe the effects of fucosylated chondroitin sulfate (FCS), a novel GAG extracted from a marine echinoderm, in experimentally induced DN compared to a widely used GAG, enoxaparin (ENX). Methods Diabetes mellitus (DM) was induced by streptozotocin in male Wistar rats divided into three groups: DM (without treatment), FCS (8 mg/kg), and ENX (4 mg/kg), administered subcutaneously. After 12 weeks, we measured blood glucose, blood pressure, albuminuria, and renal function. The kidneys were evaluated for mesangial expansion and collagen content. Immunohistochemical quantifications of macrophages, TGF- beta , nestin and immunofluorescence analysis of heparanase-1 and glomerular basement membrane (GBM) HS content was also performed. Gene expression of proteoglycan core proteins and enzymes involved in GAG assembly/degradation were analyzed by TaqMan real-time PCR. Results Treatment with GAGs prevented albuminuria and did not affect the glucose level or other functional aspects. The DM group exhibited increased mesangial matrix deposition and tubulointerstitial expansion, and prevention was observed in both GAG groups. TGF- beta expression and macrophage infiltration were prevented by the GAG treatments, and podocyte damage was halted. The diabetic milieu resulted in the down-regulation of agrin, perlecan and collagen XVIII mRNAs, along with the expression of enzymes involved in GAG biosynthesis. Treatment with FCS and ENX positively modulated such changes. Heparanase-1 expression was significantly reduced after GAG treatment without affecting the GBM HS content, which was uniformly reduced in all of the diabetic animals. Conclusions Our results demonstrate that the administration of FCS prevented several pathological features of ND in rats. This finding should stimulate further research on GAG treatment for this complication of diabetes.</abstract><doi>10.1371/journal.pone.0106929</doi></addata></record>
fulltext fulltext
identifier EISSN: 1932-6203
ispartof PloS one, 2014-09, Vol.9 (9)
issn 1932-6203
language eng
recordid cdi_proquest_miscellaneous_1611611977
source DOAJ Directory of Open Access Journals; Public Library of Science (PLoS); EZB-FREE-00999 freely available EZB journals; PubMed Central; Free Full-Text Journals in Chemistry
title The Protective Role of Fucosylated Chondroitin Sulfate, a Distinct Glycosaminoglycan, in a Murine Model of Streptozotocin-Induced Diabetic Nephropathy: e106929
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T20%3A35%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Protective%20Role%20of%20Fucosylated%20Chondroitin%20Sulfate,%20a%20Distinct%20Glycosaminoglycan,%20in%20a%20Murine%20Model%20of%20Streptozotocin-Induced%20Diabetic%20Nephropathy:%20e106929&rft.jtitle=PloS%20one&rft.au=Gomes,%20Conrado%20LR&rft.date=2014-09-01&rft.volume=9&rft.issue=9&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0106929&rft_dat=%3Cproquest%3E1611611977%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1611611977&rft_id=info:pmid/&rfr_iscdi=true